Lixarit — clinical and pharmaceutical aspects of efficacy and safety of flecainide acetate generic drug

Authors

  • N.V. Bezditko Institute for Advanced Training of Pharmacy Specialists, National University of Pharmacy, Kharkiv, Ukraine, Ukraine

DOI:

https://doi.org/10.22141/2224-1485.14.4.2021.240254

Keywords:

arrhythmia, treatment, flecainide acetate, atrial fibrillation, flecainide

Abstract

The article considers the use of flecainide, an antiarrhythmic agent. The results of comparing the bioequivalence of Lixarit, flecainide acetate generic drug (flecainide acetate, 100 mg tablets, Laboratorios Normon SA, Spain), and Apocard®, flecainide acetate reference drug (Health Care Ltd, UK, 100 mg tablets), are presented.

References

Сичов О.С., Романова О.М. Порушення серцевого ритму: коли потрібен антиаритмік та який саме? Здоров’я України. Кардіологія. Спец. випуск. 06.2020. https://health-ua.com/multimedia/userfiles/files/2020/Cardio_6_2020/Cardio_6_2020_st7.pdf

Gorenek B., Blomstrom Lundqvist C., Brugada Terradellas J. et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace. 2014. 16. 1655-73.

Hwang J.K., Park S.J., On Y.K. et al. Clinical characte­ristics and features of frequent idiopathic ventricular premature complexes in the Korean population. Korean Circ. J. 2015. 45(5). 391-7. 7.

Затонская Е.В., Матюшин Г.В., Гоголашвили Н.Г. Распространенность и клиническое значение нарушений ритма сердца. Рациональная фармакотерапия в кардиологии. 2017. 13(3). 403-408. DOI: http://dx.doi.org/10.20996/1819-6446-2017-13-3-403-408.

Жарінов О.Й. Флекаїнід в Україні: перспективи застосування для лікування передсердних і шлуночкових аритмій. Здоров’я України. Кардіологія. Ревматологія. Кардіохірургія: тематичний номер. 2017. № 3 (52). https://health-ua.com/multimedia/userfiles/files/2017/Cardio_5_2017/Cardio_5_2017_str_25.pdf.

Burashnikov A. Investigational Anti-Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020? J. Cardiovasc. Pharmacol. 2020 Nov. 76(5). 492-505. doi: 10.1097/FJC.0000000000000892. PMID: 33165131; PMCID: PMC7641178.

Bonora A., Turcato G., Franchi E., Taioli G., Dilda A., Zerman G., Maccagnani A., Pistorelli C., Olivieri O. Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs. Intern. Emerg. Med. 2017 Sep. 12(6). 853-859. doi: 10.1007/s11739-016-1497-4. Epub 2016 Jul 6. PMID: 27384766.

Hayward C., Patel H.C., Patel K., Di Mario C., Lyon A.R., Ahsan S.Y., Rowland E. The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014. Eur. Heart J. Cardiovasc. Pharmacother. 2016 Apr. 2(2). 90-4. doi: 10.1093/ehjcvp/pvv048. Epub 2015 Nov 26. PMID: 27418969; PMCID: PMC4853827.

Khan I., Patel H.C., Nanayakkara S., Raju H., Voskoboinik A., Mariani J.A. Trends in outpatient anti-arrhythmic prescriptions for atrial fibrillation and left atrial ablation in Australia: 1997-2016. Intern. Med. J. 2018 Apr. 48(4). 427-432. doi: 10.1111/imj.13706. PMID: 29205742.

Kraft M., Büscher A., Wiedmann F., L’hoste Y., Haefeli W.E., Frey N., Katus H.A., Schmidt C. Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option. Front. Pharmacol. 2021 Mar 4. 12. 638445. doi: 10.3389/fphar.2021.638445. PMID: 33897427; PMCID: PMC8058608.

Lavalle C., Magnocavallo M., Straito M., Santini L., Forleo G.B., Grimaldi M., Badagliacca R., Lanata L., Ricci R.P. Flecainide How and When: A Practical Guide in Supraventricular Arrhythmias. J. Clin. Med. 2021. 10. 1456. https://doi.org/10.3390/jcm10071456.

Andrikopoulos G.K., Pastromas S., Tzeis S. Flecainide: Current status and perspectives in arrhythmia management. World J. Cardiol. 2015 Feb 26. 7(2).76-85. doi: 10.4330/wjc.v7.i2.76. PMID: 25717355; PMCID: PMC4325304.

Liu N., Denegri M., Ruan Y., Avelino-Cruz J.E., Perissi A., Negri S., Napolitano C., Coetzee W.A., Boyden P.A., Priori S.G. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. Circ. Res. 2011 Jul 22. 109(3). 291-5. doi: 10.1161/CIRCRESAHA.111.247338. Epub 2011 Jun 16. PMID: 21680895.

Ibrahim O.A., Belley-Côté E.P., Um K.J., Baranchuk A., Benz A.P., Dalmia S., Wang C.N., Alhazzani W., Conen D., Devereaux P.J., Whitlock R.P., Healey J.S., McIntyre W.F. Single-dose oral anti-arrhythmic drugs for cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials. Europace. 2021 Mar 16. euab014. doi: 10.1093/europace/euab014. Epub ahead of print. PMID: 33723602.

Varma N., Cygankiewicz I., Turakhia M., Heidbuchel H., Hu Y., Chen L.Y., Couderc J.P., Cronin E.M., Estep J.D., Grieten L., Lane D.A., Mehra R., Page A., Passman R., Piccini J., Piotrowicz E., Piotrowicz R., Platonov P.G., Ribeiro A.L., Rich R.E., Russo A.M., Slotwiner D., Steinberg J.S., Svennberg E. 2021 ISHNE/HRS/EHRA/APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society. J. Arrhythm. 2021 Jan 29. 37(2). 271-319. doi: 10.1002/joa3.12461. PMID: 33850572; PMCID: PMC8022003.

Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2020. 14. 1-125. 10.1093/eurheartj/ehaa612 [PubMed] [CrossRef] [Google Scholar]

Muzzey M., Tellor K.B., Ramaswamy K., Schwarze M., Armbruster A.L. Flecainide is well-tolerated and effective in patient with atrial fibrillation at 12 months: a retrospective study. Ther. Adv. Cardiovasc. Dis. 2020 Jan-Dec.14.1753944720926824. doi: 10.1177/1753944720926824. PMID: 32633682; PMCID: PMC7343357.

Andrade J.G., MacGillivray J., Macle L., Yao R.J.R., Bennett M., Fordyce C.B., Hawkins N., Krahn A., Jue J., Ramanathan K., Tsang T., Gin K., Deyell M.W. Clinical effectiveness of a systematic “pill-in-the-pocket” approach for the management of paroxysmal atrial fibrillation. Heart Rhythm. 2018 Jan. 15(1). 9-16. doi: 10.1016/j.hrthm.2017.10.002. PMID: 29304952.

Alsaied T., Baskar S., Fares M., Alahdab F., Czosek R.J., Murad M.H., Prokop L.J., Divanovic A.A. First-Line Antiarrhythmic Transplacental Treatment for Fetal Tachyarrhythmia: A Systematic Review and Meta-Analysis. J. Am. Heart Assoc. 2017 Dec 15. 6(12). e007164. doi: 10.1161/JAHA.117.007164. PMID: 29246961; PMCID: PMC5779032.

Eberly L.A., Garg L., Yang L., Markman T.M., Nathan A.S., Eneanya N.D., Dixit S., Marchlinski F.E., Groeneveld P.W., Frankel D.S. Racial/Ethnic and Socioeconomic Disparities in Management of Incident Paroxysmal Atrial Fibrillation. JAMA Netw Open. 2021 Feb 1. 4(2). e210247. doi: 10.1001/jamanetworkopen.2021.0247. PMID: 33635328; PMCID: PMC7910819.

Звіт про біоеквівалентність, код протоколу дослідження N-FLE-13-189.

Законодавство України про доклінічні та клінічні випробування. https://www.dec.gov.ua/materials/zakonodavstvo-ukrayini-pro-doklinichni-ta-klinichni-viprobuvannya/

WHO Guidance for organizations performing in vivo bioequivalence studies. https://www.gmp-compliance.org/files/guidemgr/WHO_TRS_996_annex09.pdf.

Food and Drug Administration. Guidance for Industry: Bioanalytical Methods Validation. US Department of Health and Human Services, FDA, CDER; 2018. 44 р.

Published

2021-10-08

Issue

Section

To help clinicians